



JOSEPH Y. CHANG, Ph.D.

CHIEF SCIENTIFIC OFFICER,
EXECUTIVE VICE PRESIDENT OF PRODUCT DEVELOPMENT

“ageLOC is the culmination of my understanding of how the aging process happens. It’s not just about identifying the problem or the root cause of aging, but also finding a solution that can actually solve that problem.”

DEGREES AND AWARDS:

- B.S. from Portsmouth University
- Ph.D., pharmacology, University of London
- Post-doctoral research at The Johns Hopkins University School of Public Hygiene, 1981
- Arthritis Foundation fellow at The Johns Hopkins University School of Public Health, 1978-1981
- Member of American Society of Pharmacology and Experimental Therapeutics
- Member of Inflammation Research Association , 1985-1987
- Member of Reticuloendothelial Society, 1985
- Member of American Association for the Advancement of Science, 2011
- Member of The Arthritis Foundation, 1981

AREAS OF EXPERTISE:

- Changing your business model: moving from retail to direct sales
- Leveraging your research and development
- The business of nutritional supplements

MEDIA CONTACTS:

- Kara Schneck
Phone: 801-345-2116
E-mail: kschneck@nuskin.com
- Sydnee Fox
Phone: 801-345-2187
E-mail: sfox@nuskin.com

Joseph Y. Chang, Ph.D., was appointed chief scientific officer and executive vice president of Product Development in February 2006. A prolific author, Dr. Chang has published numerous articles, reviews and books on pharmacological research, including the New York Times best seller, *The Aging Myth*. With 35 years of experience in the pharmaceutical and dietary supplement industries, Dr. Chang enjoys a comprehensive knowledge of both of these industries and serves as a member of the Executive Committee for Nu Skin Enterprises. Prior to the acquisition of Pharmanex by Nu Skin Enterprises in 1998, he served as the vice president of clinical studies and pharmacology at Pharmanex.

Prior to Pharmanex, Dr. Chang served as president and chief scientific officer of Osteoarthritis Sciences, Inc., from 1991 to 1994 and Binary Therapeutics, Inc. from 1994 to 1997. He has also held various research management positions at Wyeth-Ayerst, Rhone Poulenc Rorer and other biotechnology companies, where he was involved in researching natural products for arthritis and immunosuppressive treatment. He received a B.S. degree from Portsmouth University and a Ph.D. from the University of London.

